● pepmg Research Desk · Peer-reviewed evidence review
What the research says about PNC-27
A neutral summary of the peer-reviewed literature on PNC-27, a p53/HDM-2-derived membrane-active peptide studied only in cancer-cell cultures and mouse tumor models. There are no human trials. Research use only.
Preclinical only — Animal or in-vitro studies only — no controlled human trials. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- PNC-27 is described in the literature as a 32-residue peptide that joins an HDM-2-binding domain from the p53 protein to a cell-penetrating (penetratin) leader sequence [1][4].
- In cultured cancer cell lines, studies report that PNC-27 bound to HDM-2 in the cell membrane and induced transmembrane pore formation, killing the cells by necrosis, while untransformed cells were reported to be unaffected [1][2][5].
- All of the evidence is preclinical (cell culture and mouse tumor models); there are no human trials. Reviews and animal reports describe reduced tumor growth in mice alongside a reported selectivity for cancer over normal cells [3][7][8].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What PNC-27 is
PNC-27 is characterized in the literature as a 32-residue synthetic peptide that contains an HDM-2-binding domain corresponding to residues 12-26 of the p53 protein, linked to a membrane-penetrating (penetratin) leader sequence, also called a membrane residency peptide [1][4]. HDM-2 (the human homologue of MDM2) is an E3 ligase that normally regulates p53; the research describes HDM-2 being expressed in the plasma membrane of a range of cancer cells but reported at most at low levels in the membranes of untransformed cells [2][4].
The proposed mechanism, as described across these papers, is that PNC-27 binds to membrane-associated HDM-2 and forms transmembrane pores, leading to loss of cell contents and necrosis rather than classical apoptosis [1][2]. PNC-27 is a laboratory research peptide, not an approved medicine. Material offered by third-party research-chemical vendors is sold for laboratory and research use only.
What the research has measured
Preclinical onlyThe evidence for PNC-27 is entirely preclinical: cultured cell lines and mouse tumor models. Mechanistic work reports that PNC-27 adopts an HDM-2-binding conformation and co-localizes with HDM-2 in cancer cell membranes, and that transfecting membrane-localized HDM-2 into an otherwise unaffected untransformed cell line rendered those cells susceptible, which the authors interpret as evidence that membrane HDM-2 is the target [2]. Immuno-electron-microscopy and structural studies describe ring-shaped pore structures formed by PNC-27 bound to HDM-2 at the membrane surface [1].
Across cultured human and rodent cancer cell lines, studies report that PNC-27 killed cancer cells by necrosis, measured by lactate dehydrogenase release, while control peptides and untransformed cell lines were reported to be unaffected. This has been described in leukemia cell lines [5], in a p53-deleted leukemia line where killing was reported to occur by a p53-independent pathway [6], in cultured cervical cancer cells but not their normal counterpart [10], and in primary cancer cells freshly isolated from patient ovarian tumors as well as chemotherapy-resistant ovarian lines [9]. A separate report describes PNC-27 binding to mitochondrial membranes and disrupting mitochondria in cultured pancreatic carcinoma cells [11].
In mouse models, reviews and studies report reduced tumor growth. In colon-cancer work, PNC-27 was reported to cause necrosis of tumor nodules but not of normal tissue in vivo [7], and in acute myeloid leukemia models the peptide was reported to kill leukemia cells, including stem-cell-enriched populations, while sparing normal hematopoietic stem-cell activity in transplant experiments [8]. Reviews summarize nude-mouse experiments in which the peptides reduced pancreatic and leukemic tumor burden with no off-target effects reported [3][4].
What the trials report on safety and adverse events
Preclinical onlyThere are no controlled human trials of PNC-27, so there are no human adverse-event data to report. What the abstracts describe instead is a preclinical selectivity signal: across the cell-culture studies, PNC-27 was reported to kill cancer cells while leaving untransformed control cells viable, which the authors attribute to the presence of membrane HDM-2 on cancer cells and its reported absence or low level on normal cells [1][2][5].
In the animal work, the same selectivity is described: reviews and studies report necrosis of tumor tissue but not adjacent normal tissue in mice [7], and preserved normal hematopoietic stem-cell function in leukemia transplant models [8], with reviews noting no apparent side effects in nude-mouse experiments [3][4]. These are reported observations in cells and animals, not a human safety characterization.
Because no human data exist, nothing here should be read as a safety statement for people. Material sold by research-chemical vendors is not a regulated medicine. This is not medical advice; consult a qualified professional and read the studies directly.
How strong is the evidence
The evidence for PNC-27 is characterized as preclinical: the published work is in cultured cancer cell lines (including human cancer cell lines and freshly isolated patient tumor cells) and mouse tumor models, with no human trials of any kind [3][8][9]. "Preclinical" describes the design and population of the studies, not an endorsement, and the scope matters: reports of cancer-cell killing and reduced tumor growth are observations in cells and mice, not evidence that the peptide treats cancer in people.
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 11
- PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis.
- Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes.
- Poptosis or Peptide-Induced Transmembrane Pore Formation: A Novel Way to Kill Cancer Cells without Affecting Normal Cells.
- Anti-cancer peptides from ras-p21 and p53 proteins.
- Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells.
- The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells.
- Molecular Targeting of H/MDM-2 Oncoprotein in Human Colon Cancer Cells and Stem-like Colonic Epithelial-derived Progenitor Cells.
- Targeting cell membrane HDM2: A novel therapeutic approach for acute myeloid leukemia.
- Ex vivo Efficacy of Anti-Cancer Drug PNC-27 in the Treatment of Patient-Derived Epithelial Ovarian Cancer.
- HDM-2-Targeting Peptide PNC-27 Kills Cervical Cancer Cells but not Normal Cervical Cells.
- Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.